Eiichi Kodama

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5564840/publications.pdf

Version: 2024-02-01

95 papers	4,192 citations	94433 37 h-index	118850 62 g-index
96 all docs	96 docs citations	96 times ranked	3834 citing authors

#	Article	IF	Citations
1	Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). Journal of Virology, 2008, 82, 764-774.	3.4	330
2	Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics. Journal of Medicinal Chemistry, 2006, 49, 1506-1508.	6.4	311
3	Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with Target Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Society for the Promotion of Science, and the Japan Health Science Foundation.. Angewandte Chemie - International Edition, 2002, 41, 2937.	13.8	157
4	4â€²-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2001, 45, 1539-1546.	3.2	137
5	Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Research, 2003, 58, 265-271.	4.1	127
6	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. Journal of Biological Chemistry, 2009, 284, 35681-35691.	3.4	117
7	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1897-1902.	2.2	115
8	2â€²-Deoxy-4â€²-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. International Journal of Biochemistry and Cell Biology, 2008, 40, 2410-2420.	2.8	114
9	Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochemical Pharmacology, 2000, 59, 273-281.	4.4	110
10	Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2020, 49, 18-19m.	1.9	107
11	Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of Î±-helical anti-HIV peptide analogues. Organic and Biomolecular Chemistry, 2009, 7, 2872.	2.8	105
12	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2007, 51, 2701-2708.	3.2	96
13	Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Virology, 2008, 82, 3261-3270.	3.4	88
14	Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. Journal of Virology, 2005, 79, 764-770.	3.4	87
15	Elvitegravir: A New HIV Integrase Inhibitor. Antiviral Chemistry and Chemotherapy, 2009, 20, 79-85.	0.6	86
16	Syntheses of 4â€˜-C-Ethynyl-Î²-d-arabino- and 4â€˜-C-Ethynyl-2â€˜-deoxy-Î²-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity. Journal of Medicinal Chemistry, 2000, 43, 4516-4525.	6.4	84
17	SC29EK, a Peptide Fusion Inhibitor with Enhanced Î±-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. Antimicrobial Agents and Chemotherapy, 2009, 53, 1013-1018.	3.2	82
18	Study Profile of the Tohoku Medical Megabank Community-Based Cohort Study. Journal of Epidemiology, 2021, 31, 65-76.	2.4	81

#	Article	IF	Citations
19	4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. Journal of Biological Chemistry, 2014, 289, 24533-24548.	3.4	80
20	Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. Nature Chemistry, 2015, 7, 737-743.	13.6	74
21	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4â€²-ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9274-9279.	7.1	73
22	Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Organic and Biomolecular Chemistry, 2010, 8, 616-621.	2.8	71
23	Current research on chronic active <scp>E</scp>pteinâ€“<scp>B</scp>arr virus infection in <scp>J</scp>apan. Pediatrics International, 2014, 56, 159-166.	0.5	71
24	Histone chaperone CAF-1 mediates repressive histone modifications to protect preimplantation mouse embryos from endogenous retrotransposons. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14641-14646.	7.1	68
25	Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications, 2020, 11, 1830.	12.8	64
26	Electrostatically constrained Î±-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. International Journal of Biochemistry and Cell Biology, 2009, 41, 891-899.	2.8	59
27	Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. Journal of Medicinal Chemistry, 2008, 51, 388-391.	6.4	55
28	Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Research, 1996, 31, 159-164.	4.1	54
29	2â€²-Deoxy-4â€²-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1543-1546.	1.1	49
30	Design, Efficient Synthesis, and Antiâ€HIV Activity of 4â€²â€Câ€Cyanoâ€•and 4â€²â€Câ€Ethynylâ€2â€²â€deoxy Purine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 671-690.	1.1	44
31	Delayed Emergence of HIV-1 Variants Resistant to 4â€²-Ethy Nyl-2-Fluoro-2â€²-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine, Tenofovir, Emtricitabine and BMS-986001. Antiviral Therapy, 2014, 19, 179-189.	1.0	44
32	Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway. Journal of Virology, 2008, 82, 588-592.	3.4	42
33	In Vitro Induction of Human Immunodeficiency Virus Type 1 Variants Resistant to Phosphoralaninate Prodrugs of Z -Methylenecyclopropane Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 1999, 43, 2479-2483.	3.2	41
34	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. Journal of Biological Chemistry, 2009, 284, 4914-4920.	3.4	41
35	The N348I Mutation at the Connection Subdomain of HIV-1 Reverse Transcriptase Decreases Binding to Nevirapine. Journal of Biological Chemistry, 2010, 285, 38700-38709.	3.4	41
36	Synthesis and Application of Fluoresceinâ€•and Biotinâ€Labeled Molecular Probes for the Chemokine Receptor CXCR4. ChemBioChem, 2008, 9, 1154-1158.	2.6	39

#	Article	IF	Citations
37	Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naÃ¯ve patients. Antiviral Research, 2009, 82, 115-121.	4.1	38
38	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. Journal of Biological Chemistry, 2010, 285, 39471-39480.	3.4	37
39	In Vitro Anti-Human Immunodeficiency Virus Activities of Z - and E -Methylenecyclopropane Nucleoside Analogues and Their Phosphoro- <scp>l</scp> -Alaninate Diesters. Antimicrobial Agents and Chemotherapy, 1999, 43, 1487-1490.	3.2	36
40	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology, 2013, 10, 65.	2.0	36
41	Effects of Substitutions at the 4â€² and 2 Positions on the Bioactivity of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2013, 57, 6254-6264.	3.2	35
42	Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. Journal of Immunology, 2006, 177, 3116-3122.	0.8	31
43	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4124-4129.	2.2	29
44	Procyanidin B1 Purified fromCinnamomi CortexSuppresses Hepatitis C Virus Replication. Antiviral Chemistry and Chemotherapy, 2010, 20, 239-248.	0.6	29
45	K70Q Adds High-Level Tenofovir Resistance to â€œQ151M Complexâ€•HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism. PLoS ONE, 2011, 6, e16242.	2.5	29
46	A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation. PLoS ONE, 2016, 11, e0165386.	2.5	29
47	Interactions of Conformationally Biased North and South 2â€˜-Fluoro-2â€˜,3â€˜-dideoxynucleoside 5â€˜-Triphosphates with the Active Site of HIV-1 Reverse Transcriptase. Biochemistry, 2000, 39, 11205-11215.	2.5	27
48	Anti-Herpesvirus Activities and Cytotoxicities of 2-Thiopyrimidine Nucleoside Analogues in Vitro. Antiviral Chemistry and Chemotherapy, 1999, 10, 195-209.	0.6	25
49	Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 9184-9187.	3.0	25
50	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Research, 2009, 82, 67-72.	4.1	25
51	Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structureâ€“activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 949-961.	3.0	24
52	Detection of antibodies to 65 KD heat shock protein and to human superoxide dismutase in autoimmune hepatitis-molecular mimicry between 65 KD heat shock protein and superoxide dismutase. Clinical Rheumatology, 1995, 14, 673-677.	2.2	22
53	Evaluation of Combinations of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, 2013, 57, 4554-4558.	3.2	21
54	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Research, 2010, 87, 179-186.	4.1	17

#	Article	IF	Citations
55	Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naÃ¯ve patients. Virology, 2004, 327, 215-224.	2.4	16
56	Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. Bioorganic and Medicinal Chemistry, 2004, 12, 6171-6182.	3.0	16
57	Halogenated Thymidine Analogues Restore the Expression of Silenced Genes without Demethylation. Cancer Research, 2005, 65, 6927-6933.	0.9	15
58	X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution. Journal of Molecular Biology, 2009, 392, 657-665.	4.2	15
59	Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLoS ONE, 2020, 15, e0231064.	2.5	15
60	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Research, 2012, 40, 345-359.	14.5	14
61	Construction of a Meroterpenoidâ€Like Compounds Library Based on Diversityâ€Enhanced Extracts. Chemistry - A European Journal, 2019, 25, 1106-1112.	3.3	14
62	Detection of hepatitis C virus genome in human serum by multi-targeted polymerase chain reaction. Journal of Medical Virology, 1993, 41, 6-10.	5.0	11
63	Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group. Bioorganic and Medicinal Chemistry, 2009, 17, 7964-7970.	3.0	11
64	Binding of Multivalent Anionic Porphyrins to V3 Loop Fragments of an HIVâ€1 Envelope and Their Antiviral Activity. Chemistry - an Asian Journal, 2010, 5, 825-834.	3.3	11
65	A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. PLoS ONE, 2016, 11, e0162823.	2.5	11
66	Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins. ACS Infectious Diseases, 2020, 6, 1490-1500.	3.8	10
67	Creation of Low Toxic Reverse-transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-resistant HIV Variants. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2006, 64, 716-723.	0.1	10
68	Antiviral Activity of a Sulphated Polysaccharide Extracted from the Marine Pseudomonas and Marine Plant Dinoflagellata against Human Immunodeficiency Viruses and other Enveloped Viruses. Antiviral Chemistry and Chemotherapy, 1996, 7, 189-196.	0.6	9
69	A Novel Colorimetric Assay for CXCR4 and CCR5 Tropic Human Immunodeficiency Viruses. Antiviral Chemistry and Chemotherapy, 2006, 17, 215-223.	0.6	9
70	HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors. Journal of Biological Chemistry, 2012, 287, 29988-29999.	3.4	9
71	A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats. Biochemical and Biophysical Research Communications, 2012, 424, 257-261.	2.1	9
72	Development of Small Molecule HIV-1 Fusion Inhibitors: Linking Biology to Chemistry. Current Pharmaceutical Design, 2013, 19, 1827-1834.	1.9	9

#	Article	IF	Citations
73	Inhibition of Human Immunodeficiency Virus Replication by RD6-Y664, a Novel Benzylhydroxylamine Derivative. Antiviral Chemistry and Chemotherapy, 1999, 10, 71-77.	0.6	8
74	Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. Antiviral Research, 2008, 80, 71-76.	4.1	8
75	Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins. Bioorganic and Medicinal Chemistry, 2009, 17, 7487-7492.	3.0	8
76	Inhibition of the DNA polymerase and RNase H activities of HIV-1 reverse transcriptase and HIV-1 replication by Brasenia schreberi (Junsai) and Petasites japonicus (Fuki) components. Journal of Natural Medicines, 2015, 69, 432-440.	2.3	8
77	RNase S complex bearing arginine-rich peptide and anti-HIV activity. Journal of Molecular Recognition, 2005, 18, 169-174.	2.1	7
78	Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication. Microbiology and Immunology, 1996, 40, 359-363.	1.4	6
79	Characterization of Human Immunodeficiency Virus Type 1 Strains Resistant to the Non-Nucleoside Reverse Transcriptase Inhibitor RD4â€“2217. Antiviral Chemistry and Chemotherapy, 1999, 10, 315-320.	0.6	6
80	Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4. International Journal of Biochemistry and Cell Biology, 2010, 42, 1482-1488.	2.8	6
81	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. International Journal of Biochemistry and Cell Biology, 2013, 45, 908-915.	2.8	6
82	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4035-4038.	3.2	6
83	Identification of human immunodeficiency virus type-1 Gag-TSG101 interaction inhibitors by high-throughput screening. Biochemical and Biophysical Research Communications, 2018, 503, 2970-2976.	2.1	6
84	Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus. Bioorganic and Medicinal Chemistry, 2009, 17, 4916-4920.	3.0	5
85	Synthesis of a Vpr-Binding Derivative for Use as a Novel HIV-1 Inhibitor. PLoS ONE, 2015, 10, e0145573.	2.5	5
86	Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2â€²-deoxyuridine and 5-bromo-2â€²-deoxyuridine. Antiviral Research, 1995, 27, 165-170.	4.1	4
87	Synthesis of 4â€²-C-Ethynyl and 4â€²-C-Cyano Purine Nucleosides from Natural Nucleosides and Their Anti-HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 887-889.	1.1	4
88	Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. Journal of Clinical Microbiology, 2008, 46, 792-795.	3.9	4
89	Development and application of fluorescent SDF-1 derivatives. Future Medicinal Chemistry, 2012, 4, 837-844.	2.3	4
90	Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants. MedChemComm, 2010, 1, 276.	3.4	3

#	Article	IF	Citations
91	Potent Anti-HIV-1 Activity of N-HR-Derived Peptides Including a Deep Pocket-Forming Region without Antagonistic Effects on T-20. Antiviral Chemistry and Chemotherapy, 2011, 22, 51-55.	0.6	3
92	Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral Chemistry and Chemotherapy, 2020, 28, 204020662092131.	0.6	3
93	Design and Progress of Oral Health Examinations in the Tohoku Medical Megabank Project. Tohoku Journal of Experimental Medicine, 2020, 251, 97-115.	1.2	3
94	Binding Modes of Two Novel Non-Nucleoside Reverse Transcriptase Inhibitors, YM-215389 and YM-228855, to HIV Type-1 Reverse Transcriptase. Antiviral Chemistry and Chemotherapy, 2008, 19, 133-141.	0.6	2
95	Development of a Novel Fusion Inhibitor against T-20-resistant HIV-1. Advances in Experimental Medicine and Biology, 2009, 611, 389-391.	1.6	1